Chemotherapy-induced peripheral neuropathy (CIPN) has long been recognized as a clinically significant issue in patients treated with antineoplastic drugs. This common long-term toxic side-effect which negatively impacts the outcome of the disease can lead to disability and have detrimental effects on patients' quality of life. Since axonal injury is a prominent feature of CIPN, responsible for several sensory symptoms, including pain, sensory loss and hypersensitivity to mechanical and/or cold stimuli in the hands and feet, neurophysiological assessments remain the gold standard for clinical diagnosis of CIPN. Given the large impact of CIPN on cancer patients, there is increasing emphasis on biomarkers of adverse outcomes in safety assessment and translational research, to prevent permanent neuroaxonal damage. Since the results on reliable blood molecular markers for axonal degeneration are still controversial, here we provide a brief overview of blood molecular biomarkers used for assessing and/or predicting CIPN in preclinical and clinical settings.

Meregalli, C., Bonomo, R., Cavaletti, G., Carozzi, V. (2021). Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. NEUROSCIENCE LETTERS, 749(1 April 2021) [10.1016/j.neulet.2021.135739].

Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice

Meregalli, C
Primo
;
Bonomo, R;Cavaletti, G;Carozzi, V A
Ultimo
2021

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) has long been recognized as a clinically significant issue in patients treated with antineoplastic drugs. This common long-term toxic side-effect which negatively impacts the outcome of the disease can lead to disability and have detrimental effects on patients' quality of life. Since axonal injury is a prominent feature of CIPN, responsible for several sensory symptoms, including pain, sensory loss and hypersensitivity to mechanical and/or cold stimuli in the hands and feet, neurophysiological assessments remain the gold standard for clinical diagnosis of CIPN. Given the large impact of CIPN on cancer patients, there is increasing emphasis on biomarkers of adverse outcomes in safety assessment and translational research, to prevent permanent neuroaxonal damage. Since the results on reliable blood molecular markers for axonal degeneration are still controversial, here we provide a brief overview of blood molecular biomarkers used for assessing and/or predicting CIPN in preclinical and clinical settings.
Articolo in rivista - Review Essay
Blood molecular biomarker; Chemotherapy-induced peripheral neuropathy (CIPN); microRNA; Neurofilament, metabolomics; Neurotrophins; Translational research;
English
15-feb-2021
2021
749
1 April 2021
135739
none
Meregalli, C., Bonomo, R., Cavaletti, G., Carozzi, V. (2021). Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. NEUROSCIENCE LETTERS, 749(1 April 2021) [10.1016/j.neulet.2021.135739].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/304496
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
Social impact